ANDROGEL (testosterone) by Besins Healthcare is androgen receptor agonists [moa]. First approved in 2011.
Drug data last refreshed 3h ago · AI intelligence enriched 3d ago
ANDROGEL is a transdermal testosterone gel approved in 2011 for hormone replacement in hypogonadal men. It works as an androgen receptor agonist to restore physiological testosterone levels. The product is administered topically, allowing steady-state hormone delivery without daily injections.
Nearing loss of exclusivity in October 2026; brand team focus shifting toward defensive strategies and managed decline as generic/biosimilar competition accelerates.
Androgen Receptor Agonists
Androgen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Puberty, Testosterone, and Brain Development
Worked on ANDROGEL at Besins Healthcare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moBesins Healthcare is hiring 4 roles related to this product
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on ANDROGEL offers limited career growth as the product approaches loss of exclusivity in October 2026. Professionals should expect defensive commercial strategies, portfolio transition planning, and potential role reallocation toward later-stage assets or generics support.
4 open roles linked to this drug